CelLBxHealth

What CelLBxHealth does

CelLBxHealth plc (formerly ANGLE plc, rebranded December 2025) is a UK-based liquid biopsy company specializing in the capture and molecular analysis of circulating tumor cells (CTCs). The company's core technology is the Parsortix platform, a patented label-free microfluidic system that enriches and recovers viable CTCs and CTC clusters from whole blood using a single-use cassette that isolates cells based on size and deformability. Unlike marker-dependent antibody methods, Parsortix captures a broad range of phenotypes including mesenchymal and EMT-transitioning cells, enabling downstream applications such as biomarker assessment, therapy selection, resistance monitoring, and tumor evolution studies. The platform is complemented by the CellKeep Slide harvesting technology, the Portrait+ CTC Staining Kit, and a comprehensive menu of laboratory services including CTC enumeration, immunofluorescence assays for PD-L1, HER2, androgen receptor, and DDR biomarkers, plus molecular assays for gene expression profiling and next-generation sequencing.

The company serves three primary customer segments: (1) pharmaceutical and biopharmaceutical companies requiring CTC analysis for drug discovery, clinical trial sample analysis, and companion diagnostic development; (2) diagnostic companies integrating CTC technology into molecular diagnostic workflows; and (3) contract research organizations, academic medical centers, and healthcare providers conducting translational and clinical research. CelLBxHealth monetizes through three revenue streams: pharmaceutical and laboratory services (fee-for-service custom assay development), Parsortix platform instrument sales to research laboratories, and partnership/managed-services revenue from Master Services Agreements with pharmaceutical and diagnostic partners.

In 2025 the company underwent a major strategic reset, reducing headcount by approximately 60% (from 110 to 39-44 employees), consolidating to a single Guildford facility, and pivoting from a standalone pharma services model to a partnership-led commercial strategy. FY2025 revenue was £1.4 million (down 52% year-over-year), with a £19.2M operating loss including £7.7M of restructuring charges. The company holds ISO 13485:2016, SOC 2 Type 2, and Cyber Essentials certifications, and previously obtained FDA 510(k) clearance for the Parsortix PC1 system in metastatic breast cancer (May 2022), though it subsequently discontinued its FDA establishment license. Key commercial partnerships include Master Services Agreements with AstraZeneca for clinical trial analytics, and co-marketing agreements with QIAGEN, with additional ecosystem partnerships spanning Myriad Genetics, Roche Diagnostics, and Illumina.

Name

CelLBxHealth

Legal name

CelLBxHealth plc

Website

https://cellbxhealth.com

Company type

Public

Founded year

2006

Operating status

Operating

Headcount range

101–250 employees

Short description

CelLBxHealth plc is a UK-based liquid biopsy company that develops the Parsortix microfluidic platform for label-free isolation and molecular analysis of circulating tumor cells (CTCs), serving pharmaceutical drug discovery, diagnostic development, and translational research customers through instrument sales and laboratory services.

Ownership category

akta.pro rank

Product category

Liquid Biopsy Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)

akta.pro primary industry

Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes) (HLAAAMAH)

akta.pro secondary industries

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB), Immuno-Oncology & Immune Monitoring Biomarkers (TMB, MSI, MRD, immune profiling) (HLAAAMAK)

Keywords

• Liquid biopsy diagnostics
• Circulating tumor cells
• Microfluidic cell capture
• Cancer biomarker assays
• CTC analysis services

Headquarters

HQ city

Guildford

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Services and Laboratory Services: Service laboratory providing CTC enrichment and analysis services to pharmaceutical companies for drug development, clinical trials, and biomarker discovery. Custom assay development for real-time biomarker assessment.
2. Technology Platform Sales: Parsortix platform sales to research laboratories and pharmaceutical partners for in-house CTC processing.
3. Partnership and Collaboration Revenue: Revenue from Master Services Agreements with pharmaceutical companies including AstraZeneca for biomarker development work and clinical trial sample analysis.

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

CelLBxHealth develops and commercializes the Parsortix microfluidic platform, a patented label-free system that captures and harvests viable circulating tumor cells (CTCs) and CTC clusters from whole blood based on cell size and deformability. The company complements this core instrument with consumable products (CellKeep Slide, Portrait+ CTC Staining Kit) and a menu of fee-for-service laboratory offerings including CTC enumeration, immunofluorescence biomarker assays (PD-L1, HER2, androgen receptor, DNA damage response), and molecular assays (gene expression, NGS) for pharmaceutical, diagnostic, and academic research customers.

Product overview

CelLBxHealth offers the Parsortix platform as its core product — a next-generation microfluidic system for capturing and harvesting viable circulating tumor cells (CTCs) from whole blood using patented label-free technology. The platform is complemented by the CellKeep Slide (a CTC harvesting consumable that maximizes cell retention for imaging) and the Portrait+ CTC Staining Kit (immunostaining reagents for CTC characterization). The company also provides a comprehensive menu of laboratory services including CTC enumeration, immunofluorescence assays for biomarkers such as PD-L1, HER2, androgen receptor, and DNA damage response (DDR), as well as molecular assays for gene expression profiling and NGS analysis. Together, these products and services enable pharmaceutical partners, diagnostic companies, and researchers to perform real-time CTC profiling for therapy selection, disease monitoring, and drug discovery.

Differentiator

Problem solved

Functional benefit

Brands

• Parsortix: Proprietary microfluidic platform for capturing and harvesting circulating tumor cells (CTCs) from whole blood
• Parsortix PC1
• CellKeep
• Portrait+ CTC Staining Kit
• Portrait Flex

Products and services

• Parsortix Platform Next-generation microfluidic system for enriching and recovering viable circulating tumor cells (CTCs) and CTC clusters from whole blood using patented label-free single-use cassette technology that isolates cells based on size and deformability. Includes the FDA-cleared Parsortix PC1 clinical system for metastatic breast cancer. Sold to research laboratories and pharmaceutical partners for in-house CTC processing and clinical applications.
• CellKeep Slide A unique CTC harvesting consumable that maximizes the retention of circulating tumor cells harvested from blood samples for imaging. Reduces the volume of antibody required to stain harvested CTCs, reducing processing time and costs. Sold as a standalone product compatible with the Parsortix platform.
• Portrait+ CTC Staining Kit Immunostaining kit for circulating tumor cell analysis and characterization, used in combination with the Parsortix platform. Sold as a standalone reagent kit for CTC characterization workflows.
• CelLBxHealth Laboratory Services Fee-for-service laboratory offering providing custom assay development, CTC enrichment, enumeration, and downstream molecular analysis. Includes the Portrait Flex immunofluorescence service for CTC enumeration and characterization; DNA Damage Response (DDR) immunofluorescence assay service; PD-L1 detection service; HER2 assessment service; androgen receptor detection service; and Molecular Assays service for gene expression profiling and next-generation sequencing. Sold to pharmaceutical partners, diagnostic companies, and researchers as a contracted service.

Quantifiable outcome

• CTCs detected in up to 77% of glioblastoma patients compared to less than 10% for ctDNA
• +2 more outcomes

Named customers5 records

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Five partnerships are on record, tiered core.

• AstraZenecacoreStrategic or Co-development Partner · 1 May 2026Master Services Agreement making CelLBxHealth a qualified service provider for one of the world's largest pharmaceutical companies. CelLBxHealth supports AstraZeneca's drug discovery and development through CTC-powered analytics of clinical trial samples using its proprietary Parsortix platform. This partnership drove a 30% rally in CelLBxHealth shares and is expected to lead to recurring project work over time.
• QIAGENcoreTechnology or Integration · 1 November 2025Non-exclusive collaboration and co-marketing agreement to promote the Parsortix platform and develop CTC-based research projects. Partnership aims to combine CelLBxHealth's CTC technology with QIAGEN's molecular analysis tools for drug development, biomarker discovery, and diagnostic efforts.
• AdventHealthcoreStrategic or Co-development PartnerContracting studies with AdventHealth as part of partnership-focused commercial strategy. AdventHealth represents validated partnership for CTC-based clinical research.
• Royal Marsden NHS Foundation TrustcoreStrategic or Co-development PartnerContracting studies with Royal Marsden NHS Foundation Trust, one of the UK's leading cancer research hospitals. Validated partnership supporting clinical research applications.
• Myriad GeneticscoreStrategic or Co-development PartnerValidated partnership with Myriad Genetics for diagnostic applications of the Parsortix technology platform. Collaboration for molecular diagnostic development.

Scale indicators11 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Menarini Silicon Biosystems: Develops the CellSearch system, the historical gold-standard FDA-cleared platform for enumerating circulating tumor cells in blood. Direct CTC-platform competitor to CelLBxHealth's Parsortix system, focused on similar pharma services and clinical diagnostic applications.
• RareCyte: Provides a CTC isolation and analysis platform targeting pharma biomarker research and clinical applications. Direct competitor to CelLBxHealth's Parsortix system in the CTC-based liquid biopsy market, with overlapping pharma-services offerings.
• Epic Sciences: Develops single-cell CTC characterisation technology for therapy selection and monitoring in oncology. Direct competitor to CelLBxHealth in CTC-based liquid biopsy with a similar focus on pharma services and biomarker discovery.

Broad incumbents

• Guardant Health: Leading ctDNA-based liquid biopsy company offering oncology screening, recurrence monitoring, and therapy selection tests. Competes with CelLBxHealth for the same liquid biopsy wallet share but via a different analyte (ctDNA vs CTCs).
• Natera: Specialised in cell-free DNA-based liquid biopsy tests across oncology and reproductive health. Competes with CelLBxHealth in oncology liquid biopsy applications, with a much larger commercial footprint and broader payor coverage.
• Exact Sciences: Major liquid biopsy and molecular diagnostics player with Cologuard and the Oncotype DX franchise, plus emerging oncology liquid biopsy tests. Competes for similar pharma companion diagnostic and cancer detection budgets as CelLBxHealth.
• Bio-Techne: Provides proteomics and liquid-biopsy tools including CTC-related reagents and exosome diagnostics. Sells into overlapping research and pharma-services customers as CelLBxHealth but across a broader life-science tools portfolio.

Others

• QIAGEN: Molecular diagnostics and sample-prep leader, partner of CelLBxHealth for co-marketing Parsortix. Also an indirect competitor in liquid-biopsy sample-prep and downstream analysis workflows, creating a coopetitive relationship.
• Illumina: Sequencing platform leader and CelLBxHealth integration partner. Enabler/ecosystem player for downstream NGS analysis of CTCs harvested by Parsortix, with strategic relevance but not a direct CTC-platform competitor.
• Myriad Genetics: Molecular diagnostics company with which CelLBxHealth has a validated partnership for diagnostic applications of Parsortix. Overlaps in oncology companion diagnostics, but primarily competing via germline and tissue-based molecular tests.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

• Xx.com/parsortix
• LinkedInlinkedin.com/company/angle-technology

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries2 records

Funding overview

Funding rounds4 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CelLBxHealth